Cartesian Therapeutics products
ImmTOR in Gene Therapy
ImmTOR has significant potential to mitigate unwanted immune responses and induce AAV-specific tolerance to enable redosing of gene therapies. ImmTOR has the potential to administer multiple low doses to achieve therapeutic benefit without risk of overdosing, the ability to treat patients typically excluded from these treatments and is a novel approach to treating systemic diseases resulting from genetic disorders.
Selecta Biosciences ImmTOR - Immune Tolerance Platform
Selecta Biosciences’ immune tolerance platform, ImmTOR, is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses.
Autoimmune Therapies
The current standard of care for autoimmune diseases is broad immunosuppression, which is associated with side effects and leaves patients vulnerable to serious infection and maligancies. Our approach to autoimmune disease is designed to restore natural self-tolerance by administering ImmTOR with nanoparticles-encapsulated self-antigens and avoid the need for chronic and systemic immune suppression.
ImmTOR - Enzymatic Therapy
Building upon the proven success of SEL-212, ImmTOR has exciting potential to give rise to antigen-specific immunity across a range of immunogenic compounds when co-administered with biologic therapies like enzymes.
ImmTOR + Gene Therapy Program
ImmTORTM + Gene Therapy Candidate for Methylmalonic Acidemia (MMA)
Selecta’s first ImmTORTM + gene therapy candidate MMA-101 for methylmalonic acidemia (MMA) is expected to enter clinical trials the end of 2021. MMA is a rare metabolic disease that may lead to metabolic acidosis and hyperammonemia and is associated with long-term complications including feeding problems, developmental delay, intellectual disability, and chronic kidney disease.